A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial

被引：0
|
作者：
Martinez, Imanol
Kernan, Kenneth
Piasecki, Piotr
Hamilton, Joelle P.
Goh, Chee
Arkosy, Peter
Needleman, Sarah
Ratta, Raffaele
Tadayon, Mehrnaz
Watissee, Marie
Duus, Elizabeth
Dreicer, Robert
机构：
[1] Jimenez Diaz Fdn Univ Hosp, Madrid, Spain
[2] Michigan Inst Urol, Troy, MI USA
[3] In Vivo Sp ZOO, Bydgoszcz, Poland
[4] Urol Ctr Alabama, Homewood, AL USA
[5] Royal Surrey Cty Hosp, Guildford, Surrey, England
[6] Debrecen Oncol, Debrecen, Hungary
[7] Royal Free Hosp, London, England
[8] Hop Foch, Suresnes, France
[9] TMC Pharma, Harley Wintney, England
[10] WStats, London, England
[11] Tavanta Therapeut, King Of Prussia, PA USA
[12] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5052
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
    Attard, Gerhardt
    Merseburger, Axel S.
    Arlt, Wiebke
    Sternberg, Cora N.
    Feyerabend, Susan
    Berruti, Alfredo
    Joniau, Steven
    Geczi, Lajos
    Lefresne, Florence
    Lahaye, Marjolein
    Shelby, Florence Nave
    Pissart, Genevieve
    Chua, Sue
    Jones, Robert J.
    Tombal, Bertrand
    JAMA ONCOLOGY, 2019, 5 (08) : 1159 - 1167
  • [2] A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Small, Eric Jay
    Lance, Raymond
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Stubbs, Andrew
    McCoy, Candice
    DeVries, Todd
    Redfern, Charles H.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
    John W. Smith
    Kristi J. McIntyre
    Patrick V. Acevedo
    Carlos A. Encarnacion
    Karen L. Tedesco
    Yunfei Wang
    Lina Asmar
    Joyce A. O’Shaughnessy
    Breast Cancer Research and Treatment, 2009, 118 : 361 - 367
  • [4] Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
    Smith, John W., II
    McIntyre, Kristi J.
    Acevedo, Patrick V.
    Encarnacion, Carlos A.
    Tedesco, Karen L.
    Wang, Yunfei
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (02) : 361 - 367
  • [5] Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
    Khalaf, Daniel J.
    Annala, Matti
    Taavitsainen, Sinja
    Finch, Daygen L.
    Oja, Conrad
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Sunderland, Katherine
    Azad, Arun A.
    Kollmannsberger, Christian K.
    Eigl, Bernhard J.
    Noonan, Krista
    Wadhwa, Deepa
    Attwell, Andrew
    Keith, Bruce
    Ellard, Susan L.
    Le, Lyly
    Gleave, Martin E.
    Wyatt, Alexander W.
    Chi, Kim N.
    LANCET ONCOLOGY, 2019, 20 (12): : 1730 - 1739
  • [6] A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
    McLeod, D
    Zinner, N
    Tomera, K
    Gleason, D
    Fotheringham, N
    Campion, M
    Garnick, MB
    UROLOGY, 2001, 58 (05) : 756 - 761
  • [7] (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
    Reni, Michele
    Dugnani, Erica
    Cereda, Stefano
    Belli, Carmen
    Balzano, Gianpaolo
    Nicoletti, Roberto
    Liberati, Daniela
    Pasquale, Valentina
    Scavini, Marina
    Maggiora, Paola
    Sordi, Valeria
    Lampasona, Vito
    Ceraulo, Domenica
    Di Terlizzi, Gaetano
    Doglioni, Claudio
    Falconi, Massimo
    Piemonti, Lorenzo
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1076 - 1085
  • [8] Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
    Sternberg, Cora N.
    Castellano, Daniel
    Daugaard, Gedske
    Geczi, Lajos
    Hotte, Sebastien J.
    Mainwaring, Paul N.
    Saad, Fred
    Souza, Ciro
    Tay, Miah H.
    Tello Garrido, Jose M.
    Galli, Luca
    Londhe, Anil
    De Porre, Peter
    Goon, Betty
    Lee, Emma
    McGowan, Tracy
    Naini, Vahid
    Todd, Mary B.
    Molina, Arturo
    George, Daniel J.
    LANCET ONCOLOGY, 2014, 15 (11): : 1263 - 1268
  • [9] Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial
    Zhou, Tie
    Qin, Shengfei
    Xu, Weidong
    Tang, Shouyan
    Chen, Guanghua
    Li, Song
    Hou, Jianguo
    Gao, Xu
    Shi, Guowei
    Sun, Zhongquan
    Jin, Jie
    Chen, Lijun
    Sun, Weibing
    Liu, Ben
    Wang, Jingen
    Meng, Qinggui
    Wang, Dongwen
    Hu, Zhiquan
    He, Dalin
    Yang, Yong
    Song, Xishuang
    Fu, Cheng
    Wang, Yinhuai
    Ye, Dingwei
    Zhang, Wei
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 792 - 802
  • [10] Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
    Annala, M.
    Fu, S.
    Bacon, J. V. W.
    Sipola, J.
    Iqbal, N.
    Ferrario, C.
    Ong, M.
    Wadhwa, D.
    Hotte, S. J.
    Lo, G.
    Tran, B.
    Wood, L. A.
    Gingerich, J. R.
    North, S. A.
    Pezaro, C. J.
    Ruether, J. D.
    Sridhar, S. S.
    Kallio, H. M. L.
    Khalaf, D. J.
    Wong, A.
    Beja, K.
    Schonlau, E.
    Taavitsainen, S.
    Nykter, M.
    Vandekerkhove, G.
    Azad, A. A.
    Wyatt, A. W.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2021, 32 (07) : 896 - 905
12345